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Introduction
Rhabdomyosarcoma  (RMS)  is  one  of  the  more
common  solid  tumors  in  children, with  approxi-
mately  250  new  cases  diagnosed  each  year.1 The 
roles  of  pediatric  surgeons  in  the  treatment  of 
RMS have changed signi￿ cantly through the years,
as  other  adjuvant  therapies  have  become  more 
ef￿ cacious. The  purpose  of  this  manuscript  is  to
describe  the  current  surgical  therapy  recommen-
dations of the Soft Tissue Sarcoma Committee of the
Children’s Oncology Group (COG),formerly known
as  the  Intergroup  Rhabdomyosarcoma  Group
(IRSG).
Background
The ￿ rst described case of RMS was by Webner in
1854,2 but the ￿ rst report of RMS in children was not
until 1952, by Pack et al.3 During those early years,
surgery was the only therapy used,and often involved
radical excision of tumor and normal tissue, includ-
ing  amputation  and  exenteration. Even  with  that
aggressive surgical intervention,survival rates of only
7–70%,depending on tumor site,were achieved.4,2 In
1961, the  addition  of  high-dose  chemotherapy
resulted in a signi￿ cant improvement in survival. In
1965, the  addition  of  high-dose  radiation  therapy
with chemotherapy and surgical excision also led to
an  improvement  in  patient  survival. Noting  that
chemotherapy,radiation,and surgery all had a part in
the  treatment  of  RMS, the  Intergroup  Rhabdo-
myosarcoma  Study  Group  (IRSG)  was  formed in
1972.This group was charged with developing a mul-
tidisciplinary approach to  the  treatment  of  RMS.7
Since  its  inception, IRSG  has  enrolled  over  3000
patients and has signi￿ cantly improved overall sur-
vival  rates  for  RMS. Currently, IRSG  is  enrolling
patients in IRS-V.
Surgeons continue to  have  a  pivotal  role  in the
treatment of RMS.The goal of this manuscript is to
provide guidelines to surgeons for the care of RMS
patients. Surgeons are involved in the preoperative
staging  and  postoperative  grouping  of  patients, as
well as biopsy and excision of tumors.
Epidemiology
Rhabdomyosarcoma  is  not  an  uncommon  tumor,
accounting  for  5%  of  all  pediatric  solid  tumors.2
There  are  approximately  4  million  cases/million
population/year;1 250  new  cases  of  RMS  in  the
United States each year.The median age at presen-
tation  is  5  years; however, this  seems  to  follow  a
bimodal distribution with peak incidences between 2
and 4 years and between 12 and 16 years.Therefore,
approximately 80% of RMS cases have occurred by
14 years of age.8 There is a slight male preponder-
ance, with a male to female ratio of 3 to 2.
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there  appears  to  be  some  genetic  predisposition.
Certain risk factors  have  been identi￿ ed, including 
Li Fraumeni syndrome,in which patients present with
RMS  at  an  early  age  and  have  a  family  his-
tory  of  other carcinomas, especially premenopausal
breast carcinoma.9 This syndrome is an autosomal-
dominant disorder and is usually associated with a
germline mutation of p53.10 Other possible risk factors
for RMS include neuro￿ bromatosis, nevoid basal cell
carcinoma, fetal  alcohol  syndrome, and  maternal 
exposure to marijuana or cocaine,X-rays,and employ-
ment as a healthcare worker.11–14
Pathology
Rhabdomyosarcomas arise from primitive mesenchy-
mal cells that are present throughout the body, even
in areas that are usually not associated with striated
muscle.15 However, all tumors show some degree of
striated muscle differentiation. Rhabdomyosarcomas
may invade local structures and frequently metasta-
size  early  through  lymphatics  or  hematogenous
spread.Tumors are usually ￿ rm,nodular,and variable
in size and consistency; however, they are not encap-
sulated and invade surrounding soft-tissue structures.
There are essentially four types of RMS: embryonal,
alveolar,pleomorphic,and undifferentiated.7 Embry-
onal is the most common and is usually found in chil-
dren less than 8 years old.Embryonal also constitutes
80% of all genitourinary (GU) RMS and 60% of head
and neck RMS.Within the embryonal type, there are
two subvariants including spindle-cell RMS,which is
common in paratesticular lesions,and botryoid RMS,
which  is  found  in  mucosa-lined  hollow  viscera.
Overall, patients  with  embryonal  RMS  have  good
prognoses, with a 5-year survival rate of 60%. For
spindle cell and botryoid subvariants the survival rate
increases to 95%. Alveolar RMS is found in older 
children and is associated with tumors in the extrem-
ities  and  trunk. Patients  with  alveolar  RMS  have
slightly worse prognoses than those with embryonal,
with  an  average  5-year  survival  rate  of  54%.
Pleomorphic RMS also involves the limbs and trunk;
however, patients with it have better prognoses than
those with alveolar, with a 75% 5-year survival rate.
Patients with undifferentiated RMS have the worst
prognoses,with a 40% survival rate and tumors in the
limbs, head, and neck areas.
Preoperative evaluation
Presentation
Most RMS tumors present as asymptomatic masses
detected by patients or their families. Some tumors
present with signs and symptoms that vary according
to primary tumor origin and may be secondary to
mass effect or complications of the tumor.
Preoperative workup
Patients  with  suspected  RMS  require  a  complete
workup before de￿ nitive surgery.This includes stan-
dard  blood  work  such  as  complete  blood  counts
(CBC), electrolytes  and  renal  function  tests, liver
function tests (LFTs),and urinalysis (UA).There are
no  serum  tumor  markers  for  RMS. The  primary
tumor should be  evaluated  with  computer tomog-
raphy (CT) or magnetic resonance imaging (MRI).16
MRI  provides  better  de￿ nition  of  the  tumor  and
surrounding structures, therefore is preferable, espe-
cially  for  limb, pelvic, and  paraspinal  lesions. CT 
is  probably  better  for  evaluation  of  bone  erosion 
and abdominal adenopathy.17 Metastatic evaluation
includes a bone marrow aspirate and bone scan, CT
of the brain, lungs, and liver, and lumbar puncture
for cerebrospinal ￿ uid (CSF) collection. Metastatic
tumor can also be detected using a gallium scan.18
Pretreatment clinical staging 
This is a modi￿ cation of the TNM staging system and
is based on primary tumor site, primary tumor size,
clinical regional nodal status, and distant spread19,20
(Table 1). These criteria were the best predictors of
survival in nonmetastatic patients during the IRSG II
study. Staging is based on clinical ￿ ndings, such as
preoperative  imaging  and  physical  ￿ ndings, and
should be done by surgeons and oncologists. Size of
the tumor should be determined by physical examina-
tion or imaging measurements. Careful evaluation of
clinical  and  imaging  ￿ ndings  is  imperative  before
assignment of primary tumor site because site desig-
nation  alters  stage  and  treatment  assignment.
Intraoperative  ￿ ndings  and  pathological  results
should not affect stage (but will affect Clinical Group).
Surgical principles
Biopsy
Frequently the initial procedure for patients with a
mass suspected to be RMS is a biopsy, usually open,
which obtains an adequate specimen for patholog-
ical, biological and treatment protocol studies.There
may be instances when core needle biopsy is appro-
priate, such as metastatic disease or small lesions in
areas that will be treated primarily by chemotherapy
and radiotherapy.21,22
Neoadjuvant therapy
After staging studies some tumors will be declared
unresectable because of their large size or approxi-
mation to vital structures. Neoadjuvant therapy may
shrink  tumors, converting  unresectable  tumors  to
resectable or decreasing resection morbidity. Results
of  IRSG  studies  have  shown  the  ef￿ cacy  of
chemotherapy for tumor shrinkage and subsequent
112 Rodeberg et al.resection.23,24 In  these  studies, Group  III  patients
treated  with  chemotherapy  followed  by  complete
excision had prognoses similar to Group I patients.
Node sampling or dissection
Clinical or radiographic evaluation of regional lymph
nodes should be done during diagnostic workup and
is an important component of pretreatment staging
(Table 2). Clinically positive nodes should always be
con￿ rmed  pathologically. Open  biopsy  is  recom-
mended; however, core needle biopsy or ￿ ne needle
aspiration  may  be  appropriate, based  on  the
surgeon’s judgment and pathologist’s recommenda-
tions.25,26 For  multiple  clinically  positive  nodes,
radical debulking may be useful, with radiotherapy,
to obtain regional control.27,28 During biopsy of the
regional  lymph  nodes, a  ‘distant’ node  should  be
harvested for pathological study.For upper extremity
lesions this would consist of an ipsilateral supraclav-
icular (scalene) biopsy, for  the  lower extremity  an
iliac and/or para-aortic node biopsy, and for parates-
ticular the ipsilateral para-aortic lymph node at the
renal vein.Involvement of these distant nodes is anal-
ogous  to  metastatic  disease.27 There  is  no  bene￿ t
from  formal  nodal  dissection  if  distant  node  or
metastatic disease has already occurred.
Pathological  evaluation  of  clinically  uninvolved
nodes is site speci￿ c; it is required in extremity sites27
and for children older than 10 years with paratestic-
ular tumors (manuscript in preparation). Aggressive
regional  lymph  node sampling is  the  most  appro-
priate method of surgical evaluation since resection
is  diagnostic  but  not  therapeutic. For this  reason,
prophylactic  radical  node  dissection, as  used  for
some other malignancies, is not necessary in child-
hood rhabdomyosarcoma.
Sentinel node mapping using blue dye,radioactive-
labeled  colloid  or  both  is  helpful  in  determining
regional  node  status.29 Preliminary  data  from  the
IRSG suggest that sentinel node biopsy may be effec-
tive (unpublished).We anticipate that sentinel lymph
node biopsy will become the standard of care for the
next IRSG study.
Margins
The basic principles of wide and complete resection
of the primary tumor with a surrounding ‘envelope’of
normal tissue should be followed at the initial,or sub-
sequent, operations whenever possible. A somewhat
arbitrary margin of 0.5 cm circumferentially, or an
uninvolved fascia margin, are adequate.This size of
margin  generally  is  more  easily  obtained  in  the
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Table 1. TNM pretreatment  staging classi￿ cation. Staging before treatment  requires thorough  clinical, laboratory, and imaging
examinations.Biopsy is required to establish histological diagnosis. Pretreatment tumor size is determined by external measurement or
MRI or CT,depending on anatomic location.For less accessible primary sites,CT also will be used for lymph node assessment.Metastatic
sites will require some form of imaging (but not histological con￿ rmation,except for bone marrow examination) con￿ rmation.
Stage Sites T Size N M
1 Orbit T1 or T2 a or b N0 or N1 or Nx M0
Head and neck (excluding
Parameningeal)
GU nonbladder/
Nonprostate
2 Bladder/Prostate, T1 or T2 a N0 or Nx M0
Extremity, Cranial
Parameningeal, Other
(Includes trunk,
Retroperitoneum, etc.)
3 Bladder/Prostate, T1 or T2 a N1 M0
Extremity, Cranial b N0 or N1 or Nx M0
Parameningeal, Other
(Includes trunk,
Retroperitoneum, etc.)
4 All T1 or T2 a or b N0 or N1 M1
De￿ nitions Tumor T(site)1 con￿ rmed to anatomic site of origin
(a)  <5 cm in diameter; (b) >5 cm in diameter
T(site)2 Extension and/or ￿ xative to surrounding tissue
(a)  <5 cm in diameter; (b) >5 cm in diameter 
Regional nodes
N0 regional nodes not clinically involved
N1 regional nodes clinically involved by neoplasm
Nx clinical status of regional nodes unknown (especially sites that 
preclude lymph node evaluation)
Metastasis
M0 no distant metastasis
M1 metastasis presentextremities or trunk than in head and neck tumors.
Adequate margins of uninvolved tissue are required
unless excision involves sacri￿ ce of normal tissue that
cannot be resected, would result in an unacceptable
loss of function/cosmesis, or is not technically feasi-
ble.The surgeon should mark all margins and orient
the specimen at the operative ￿ eld, so that margin
evaluation is precise. Narrow margins are unavoid-
able in some sites. In those situations, the surgeon
should take several separate biopsies of the ‘normal’
tissue  around  the  margins  of  resection  and  these
should  be  marked  and  submitted  separately  for
pathological review.Communication with the pathol-
ogist  is  mandatory  to  assure  accuracy  of  margin
examination.The tumor should not be bisected or cut
into  separate  specimens  before  being  sent  to  the
pathologist. Any  suspected  microscopic  or  gross
residual tumor should be marked in the tumor bed
with small titanium clips to aid radiotherapy simula-
tion and subsequent re-excision.Adequate margins of
normal tissue are preferable to leaving gross or micro-
scopic residual diseases in all circumstances. A clear
margin and no residual disease (Group I) is superior
to microscopic margins (Group II) or gross residual
disease (Group III) in all outcomes analyses.30,31,24.
Exceptions to this operative approach would be pri-
maries in the orbit, head and neck, biliary, and GU
sites.32–36 Also, when the RMS arises from a somatic
muscle, excision of the entire muscle of origin or the
entire compartment usually is not necessary.37
The initial surgical procedure may have been done
before the diagnosis of RMS was established. This
frequently results in an incisional biopsy or a limited
excision of the RMS mass similar to that used for
benign tumors. This situation frequently results in
gross  residual  tumor, microscopically  involved
margins, or uncertainty about the margins. Under
these circumstances, pretreatment re-excision (PRE)
is advisable.PRE is a wide re-excision of the previous
operative  site, including  an  adequate  margin  of
normal  tissue, with  careful  examination  of  all
margins before adjuvant therapy. PRE is particularly
applicable to extremity and trunk lesions, but should
be  applied  whenever  feasible  (unless  re-excision
involves  sacri￿ ce  of  normal  tissue  that  cannot  be
resected, would  result  in  an  unacceptable  loss  of
function/cosmesis,or is not technically feasible).PRE
improves failure-free survival and, more importantly,
overall survival.30
Clinical group
Clinical group assignment is determined postopera-
tively  based  on  pathology  examination  from  the
de￿ nitive operation. Grouping results in the strati￿ -
cation of patients based on completeness of excision
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Table 2. Regional nodal basins for rhabdomyosarcoma
Extremity
Lower extremity-inguinal, femoral, popliteal nodes (rarely involved)
Upper extremity-axillary, brachial, epitrochlear, infraclavicular nodes (infraclavicular)
Genitourinary
Bladder/prostate-pelvic, retroperitoneal nodes at renal artery level or below
Cervix and uterus-pelvic, retroperitoneal nodes at renal artery level or below
Paratesticular-pelvic, retroperitoneal nodes at renal artery level or below
Vagina-retroperitoneal, pelvic nodes at or below common iliacs inguinal nodes
Vulva-inguinal nodes
Head and neck
Head/neck-ipsilateral cervical, jugular, preauricular, occipital, supraclavicular nodes for laterally placed tumors 
(excluding scalp); may have bilateral adenopathy with centrally placed tumors
Orbit/eyelid-ipsilateral jugular, preauricular, cervical nodes
Intrathoracic
Intrathoracic-internal mammary, mediastinal nodes
Retroperitoneum/pelvis
Retroperitoneum/pelvis-pelvic, retroperitoneal nodes
Trunk
Abdominal wall-inguinal, femoral nodes
Chest wall-axillary, internal mammary, infraclavicular nodes
Other
Biliary-liver hilar nodes
Perianal/perineal-inguinal, pelvic nodes; may be bilateral
Notes: any tumor-involved node other than those listed above signi￿ es distant metastasis (Stage 4/Group IV). Examples: perineal primary
with nodes above the pelvis; thigh primary with iliac or periaortic nodes; intrathoracic primary with subdiaphragmatic nodes; paratestis
primary with inguinal nodes with or without trans-scrotal biopsy or scrotal involvement.We would like to thank Dr. Bev Raney for use of
this table.and lymph  node status  (Table  3). Strati￿ cation  of
clinical  groups  correlates  closely  with  long-term
survival and prognosis.38 Patients with an incisional
biopsy are considered Group III if no further surgery
is  performed. However, for  patients  who  undergo
PRE, the ￿ nal Group is based on the pathological
results from the PRE.
Secondary procedures
Operating again to determine response status after
chemotherapy and radiotherapy may be considered
for  patients  who  are  deemed  to  have  partial
responses, and selected nonresponders.The purpose
of  second-look  operations  is  to  con￿ rm  clinical
response, to evaluate pathological response, and to
remove residual tumor to achieve local control.39,40
CT or MRI should be used to evaluate patients for
residual local and metastatic disease.In IRS III, 75%
of patients classi￿ ed as having partial responses by
imaging  were  found  to  have  complete  responses
during second look operations or were converted to
complete responses by excision of residual tumors.41
Converting  them  to  complete  responses improved
their survival.The second look operations were most
effective  in  extremities  and  trunks  compared with
head and neck lesions. Flaps and/or grafts  may be
required for reconstruction, especially because prior
radiation can affect wound closure and healing. For
intracavitary  sites, such  as  abdomen  or  thorax, a
complete second-look evaluation using open, laparo-
scopic, or  thorascopic  evaluation  can  be  done. If
imaging or clinical evidence of residual disease exists
but total excision is not possible, diagnosis should be
con￿ rmed by biopsy. However, complete resection
should be the goal of the second-look operation.
Chemotherapy
Chemotherapy  was  recognized  as  an  important
adjunct to  surgery  in  the  1980s42,43 and today  all
patients with RMS receive some form of adjunctive
chemotherapy. The  standard  is  a  combination  of
vincristine, actinomycin, and  cyclophosphamide
(VAC). Some patients with more favorable disease
receive only VA.
Radiotherapy
Radiotherapy  is  an  important  adjunct  for  local
control of RMS. Currently all patients receive 40–60
Gy unless they  have  group I  nonalveolar RMS or
tumors of the GU tract (vagina, uterus, vulva) that
are excised completely after chemotherapy.The XRT
port includes the tumor bed plus a 2-cm margin and
should  include  the  lymph  node  basin  if  nodal
metastatic disease has been found.
Speci￿ c anatomic sites
There are some site-based pathological and biolog-
ical  variations  between tumors that  require differ-
ences in surgical management.
Head and neck (super￿ cial nonparameningeal)
Head and neck lesions encompass orbital, parotid,
buccal, laryngeal, and oropharyngeal locations.Wide
excision is appropriate when feasible,but the possibil-
ity of achieving wide margins is restricted generally to
patients with relatively super￿ cial lesions who present
early. Cosmetic and functional factors always should
be  considered. For  some  tumors, such  as  parotid,
laryngeal, oropharyngeal  and  other  deep  tumors,
surgery is limited to biopsy followed by chemotherapy
and  XRT  for  tumor  eradication.44 This  treatment
scheme  results  in  good  survival  rates  of  83%.45,46
However, for most tumors the standard combination
of  surgery, chemotherapy, and  radiotherapy  are
applicable, with the same surgical principles of com-
plete excision used for other sites.47–49The incidence
of  cervical  node involvement  is  quite  low  in  head 
and neck primaries.28 Cervical lymph node biopsy is
not required unless nodes are involved clinically.RMS
of the orbit is, in many respects, quite different from
that arising in other head and neck sites.The progno-
sis is better and biopsy followed by chemotherapy and
radiotherapy has become the standard of care.50–52
Parameningeal
Similar to other head and neck lesions, wide excision
is  appropriate  when  feasible, but  achieving  wide
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Table 3. Intergroup rhabdomyosarcoma study clinical grouping system
Group I Localized disease, completely resected
A. Con￿ rmed to organ or muscle of origin
B. In￿ ltration outside organ or muscle of origin; regional nodes not involved
Group II Compromised or regional resection including
A. Grossly resected tumors with microscopic residual tumor
B. Regional disease, completely resected, with nodes involved and/or tumor extension into an 
adjacent organ
C. Regional disease, with involved nodes, grossly resected, but with evidence of microscopic 
residual tumor
Group III Incomplete resection or biopsy with gross residual disease remaining
Group IV Distant metastases present at onsetmargins is usually only possible for patients with rela-
tively  super￿ cial  lesions. Craniofacial  resection for
anterior  skull-base  tumors  of  the  nasal  areas,
paranasal  sinuses, temporal  fossa, and  other  such
sites should be reserved for expert surgical teams.48
Resection also should be limited to secondary proce-
dures when tumors persist after initial chemotherapy
and radiotherapy. Cervical lymph node biopsy is not
required unless nodes are involved clinically.
Trunk
The category ‘trunk’ RMS includes paraspinal, tho-
racic, intra-abdominal, retroperitoneal and abdomi-
nal  wall  locations. These  lesions  frequently  have
alveolar histologies (40% alveolar, 20% embryonal)
and  like  extremity  lesions  poor  responses  to
chemotherapy with subsequent poor prognoses, with
an  over-all  5-year  survival  rate  of  50%.53 Unlike
extremity lesions, truncal RMS has a lower incidence
of nodal metastatic disease and is more likely to have
local recurrence.
Paraspinal
Paraspinal  RMS  excision  is  frequently  incomplete
because of tumor proximity to the vertebral column
and spinal canal,and large tumor size at presentation
(usually greater  than  5  cm).54 Patients  with  large,
bulky, unresectable tumors may  bene￿ t  from neo-
adjuvant  chemotherapy  followed  by  resection.55
Regardless of neoadjuvant therapy, if patients have
postoperative micro- or macroscopic residual disease,
they will require XRT.However,if a paraspinal tumor
does  respond  to  induction  chemotherapy, then  a
second-look  operation  with  wide  local  excision
should be done to completely excise the tumor and
obviate the need for XRT.
Abdominal wall
Most abdominal wall primaries can be removed com-
pletely,either at presentation or during a second-look
operation after neoadjuvant chemotherapy. Excision
should include the full thickness of the abdominal
wall, including peritoneum and overlying skin,en bloc
resection of  any  local  extension, and  a  margin  of
normal tissue. A recent study by Beech et al. sug-
gested that long-term outcomes for these patients is
affected by micro- or macroscopic residual disease,
age, and  alveolar  histology. If  size  or  location  of
tumors does not allow adequate excision, then initial
biopsy should be followed by chemotherapy with sub-
sequent  evaluation  for  excision  after  3  months  of
therapy. If  complete  resection  is  accomplished  at
diagnosis or second-look operation, no postoperative
XRT is required.Abdominal wall reconstruction can
be done using mesh or myocutaneous muscle ￿ aps,
with excellent results.These repairs can generally be
accomplished  while  preserving  good  function  and
cosmesis.
Chest wall
Many  other  types  of  sarcomas, such  as  Ewing  or
primitive  neuroectodermal  tumor  (PNET), can
present as chest-wall masses.Therefore, initial biop-
sies should be done for all chest-wall tumors. The
proper subsequent therapy is determined by histol-
ogy. The biopsy should always be done on the long
axis of the tumor,which is parallel to the ribs. Once a
diagnosis  of  RMS  is  established, unless  complete
excision  is  believed  to  be  feasible, chemotherapy
should be initiated.After 3 months of chemotherapy,
patients  can  be  evaluated  with  imaging  studies to
consider complete tumor excision. Thoracoscopy is
sometimes bene￿ cial to determine pleural extent of
tumors and the presence of attachments to underly-
ing lung. An excision should be wide, removing the
full thickness of the chest wall,including the previous
biopsy site,involved chest wall muscles,involved ribs,
and may require wedge excision of underlying lung.
It is not necessary to remove the entire length of the
rib. Also, it is not necessary to remove the rib above
and below if a wide margin can otherwise be accom-
plished. Sometimes removal of the periosteum of the
rib  above  and  below  will  allow  adequate  margins
while preserving the rib. Because of high local recur-
rence  rates  it  has  been  recommended that  wider
margins than usual should be attempted, preferably 
2  cm. Reconstruction  can  be  accomplished  with
mesh  or  myocutaneous  muscle  ￿ aps. Sometimes
bone struts are necessary,using homografts, rib from
the contralateral side, or titanium rib implants. If the
tumor  is  completely  removed  with  no  macro  or
microscopic residual disease, no postoperative radio-
therapy is required. However, there has been some
suggestion, given the high recurrence rate of chest-
wall disease,that adjuvant XRT may be bene￿ cial for
all  patients.57 Chest-wall  lesions have  worse  prog-
noses than other trunk lesions because of high local
and distant recurrence rates, with a 1.8-year survival
rate of only 42%.57
Retroperitoneum/pelvis
RMS of  the  retroperitoneum and pelvis is  usually
large and the exact site of origin is dif￿ cult to deter-
mine.These tumors usually are so large and envelop
so  many  vital  structures  they  are  unresectable  at
presentation; however, the same basic surgical prin-
ciples apply. Patients with tumors believed resectable
should undergo complete excision.When successful
initial  resection  is  unlikely, biopsy  for  diagnosis
should be performed followed by chemotherapy and
secondary resection attempts. Success with aggres-
sive  resection, including vena  cava  and  aorta, has
been reported.58 Aggressive resection should not be
done for patients with Group IV metastatic disease
116 Rodeberg et al.because survival is not improved in these patients by
primary tumor resection.However,group IV patients
with embryonal histologies, particularly those under
10 years old, do relatively well regardless of residual
disease.This conclusion stems from the observation
that there is improved failure-free survival if surgical
debulking is done during initial surgery, rather than
biopsy alone.59Therefore, in this site, for this patient
age, and  with  embryonal  histologies  only, tumor
debulking without sacri￿ ce of important structures
or function can be considered.
Biliary
Patients with tumors of the biliary system do rela-
tively well with chemotherapy and radiotherapy and
without  aggressive  surgery  because  they  usually 
have  the  botryoid  variant  of  embryonal  RMS
histology.35,60,61 The primary role of surgery often is
for diagnosis and staging. If tumor excision can be
accomplished without radical resection it should be
attempted because survival is improved for patients
with  microscopic  residual  disease  compared  to
macroscopic  or  gross  residual  disease. Relief  of
biliary  obstructions  is  likely  with  chemotherapy;
therefore attempts to establish biliary drainage with
aggressive  intervention  are  unnecessary. Likewise,
external  drainage  of  the  biliary  system  while  the
patient is immunosuppressed with chemotherapy is
associated with a high incidence of sepsis.35
Perineum/perianal
Perineal and perianal RMS are often large tumors
(greater  than  5  cm). There  is  100%  failure-free
survival  with  completely resected Group I  tumors
compared with 24% for metastatic disease group IV
tumors (Blakely ML, submitted). Thus, if complete
resection while  maintaining function  is  feasible, it
should  be  attempted. Long-term  patient  survival
declines  dramatically  as  the  amount  of  residual
disease and patient age increases.The same surgical
principles for other trunk sites apply to these lesions.
Occasionally, a temporary colostomy is necessary if
there is anorectal obstruction.
Extremity
Extremity  RMS  is  characterized  by  a  higher  inci-
dence  (50%)  of  patients  with  alveolar  histology.
Alveolar RMS is most common in the proximal lower
extremities. Regional  lymph  nodes  are  positive  in
10–25%  of  patients. This  high  rate  of  nodal
metastatic disease negatively affects survival, with a
46%  survival  rate  for  node-positive  patients
compared with 80% for node-negative.62,63
Extremity  tumors  often  can  be  widely  resected
while sparing the involved limb.Radical soft tissue or
compartmental  excision  generally  provides  a  wide
margin  that  is  suf￿ cient  for  local  tumor  control.
Excision of an entire muscle from origin to insertion
or resection of an entire compartment may not be
required, depending on the size and invasiveness of
the speci￿ c tumor. Rarely is amputation required for
tumor excision.The importance of complete excision
cannot  be  overstated  because  survival  is  70–91%
with microscopic residual disease or complete exci-
sion  and  only  23–50%  with  metastatic  or  gross
residual disease.62,67Also,the survival rate for incom-
plete  resection  is  no  better  than  incisional  biopsy
alone.57 Approximately half of children who die from
these tumors have local recurrences;64 therefore, if
residual tumor  is  known  or  suspected after  initial
resection, a PRE should be done to excise the tumor
before other treatment is begun.
Regional  lymph  node  evaluation  is  integral  in
staging patients with extremity RMS.27 Systematic,
aggressive inguinal or axillary lymph node sampling
is required even when there are no clinically involved
nodes. Axillary dissection with preservation of pec-
toral muscles, long thoracic nerve, and thoracodorsal
nerve has low morbidity and is the best sampling pro-
cedure for upper extremity lesions. Femoral triangle
node sampling, rather than a formal node dissection,
is recommended for lower extremity lesions. If nodes
are involved clinically, biopsy of more central nodes
should be done before regional sampling. For lesions
of the upper extremity this involves ipsilateral supra-
clavicular (scalene) node biopsy and for the  lower
extremity, iliac  or  para-aortic  node  biopsy.
Involvement  of  these  central  nodes  is  considered
distant metastatic disease (Clinical Group IV) rather
than  regional  involvement, and  therefore  will  be
important  in  determining  subsequent  adjuvant
therapy and prognosis. If regional nodes are involved
then XRT ￿ elds are adjusted to incorporate regional
lymph  nodes. Incorporation  of  disease-positive
regional nodes into the XRT ￿ eld is associated with
lower local and regional recurrence rates.65
Genitourinary: bladder/prostate
RMS of  the  bladder and prostate usually is large,
unresectable, and  of  embryonal histology. Bladder
salvage is an important goal of therapy and can be
anticipated in 50–60% of patients.26 Tumors rarely
may be completely resectable at presentation, with
preservation of bladder and urethral function; how-
ever, in most patients the initial operative procedure
consists  of  biopsy  done  endoscopically, perineally,
suprapubically, or occasionally by laparotomy. Once
the diagnosis is con￿ rmed, pretreatment staging of
tumor  size  by  CT  scanning  and  cystogram  are
required. If laparotomy is performed, iliac and para-
aortic node sampling should be included, as well as
biopsies of any other clinically involved nodes. After
diagnosis  and  pretreatment  staging, chemotherapy
and radiotherapy are initiated. Neoadjuvant therapy
frequently  results  in  tumor  shrinkage  and  necro-
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extent of disease should be reevaluated. If complete
resection is possible surgeons should proceed to oper-
ation. Partial cystectomy has resulted in similar sur-
vival  rates  and  higher  rates  of  functional bladders
compared with other treatment options.36,67 Partial
cystectomy  usually is  performed for bladder-dome
tumors but may be applicable to more distal bladder
lesions. These distal bladder resections may require
ureteral  reimplantation  or  bladder  augmentation.
Rarely, the response of prostatic tumors to neoadju-
vant  therapy  may  allow  prostatectomy  to  be  per-
formed  with  complete  tumor  removal  and
preservation  of  the  urethra  and  bladder. Prostate
RMS more commonly requires prostatectomy, blad-
der salvage, and ureteral reconstruction.68 Complete
response  to  nonoperative  therapy  may  not  be 
rapid, so  as  long  as  there  is  continued  partial
response, radical resection (e.g., pelvic exenteration)
should be delayed.If the tumor is still unresectable or
not responding to medical therapy,then radical resec-
tion of all disease should be done and the patient
should be provided with a continent urinary diver-
sion. The  treatment  algorithm  of  biopsy, medical 
therapy, then  second-look operation  has  improved
survival  (60–80%)  and  bladder  preservation  rates
(83%).36,67,70,71,26 RMS arising from the bladder has a
better prognosis than prostrate probably because of
ease and completeness of tumor excision.
Paratesticular
Paratesticular RMS usually presents early as Group I
disease that is resected easily.72,73Most tumors present
as  painless  scrotal  masses.74 Paratesticular  RMS
tumors are usually a variant of embryonal histology
called spindle cell that has a very good prognosis with
survival rates >90% for Groups I and II patients.75,76
Lesions adjacent to the testis or spermatic cord should
be  removed by  orchidectomy and  resection of  the
entire  spermatic cord  through  an  inguinal incision
with proximal control of the spermatic cord.The con-
tralateral testis should be transposed to the adjacent
thigh, temporarily, when  scrotal  radiotherapy  is
required. Open biopsy or tumor spillage of any kind
should be avoided because inguinal recurrence may
follow.If biopsy is believed necessary before orchidec-
tomy, the  following  steps  should  be  followed: (1)
atraumatic  high  control of  the  spermatic cord; (2)
mobilize the testis and cord carefully isolated from the
operative ￿ eld using a nonpermeable plastic bag; (3)
biopsy site closed and testes covered while awaiting
frozen section report;(4) instruments used for biopsy,
gowns,and gloves changed;(5) if biopsy report is pos-
itive, testes and the entire cord including the atrau-
matic clamp should be immediately removed without
removing the protective dressing or atraumatic clamp;
(6) the ￿ eld should be thoroughly irrigated. Patients
with  unprotected  spillage  are  considered  Clinical
Group IIa regardless of the completeness of resection.
The incidence of nodal metastatic disease for parat-
esticular RMS is 26 - 43%.77,73,78 All patients with
paratesticular primary tumors should have thin-cut
abdominal and pelvic CT scans with IV and PO con-
trast to evaluate for evidence of nodal involvement.
Regional  lymph  nodes are  the  ipsilateral  iliac  and
retroperitoneal nodes up to the upper pole of the ipsi-
lateral  kidney. Any  suspicious  nodes  on  CT  scan
should  be  considered positive  (Group  IIb)  unless
pathologically proven to be negative. However, stud-
ies have found that retroperitoneal lymph node status
staged with CT scans may be incorrect for 58% of
patients.79 A review of IRSG patients indicated that
lymph node sampling is not necessary in children less
than 10 years old who have paratesticular RMS and
negative CT scans. However, patients with enlarged
nodes on CT scans, or children older than 10 years
are  required  to  have  careful  systematic  ipsilateral
nerve-sparing  retroperitoneal  node  dissection with
pathological evaluation for metastatic disease.These
two groups of patients, enlarged nodes or children
older than 10, have a much higher incidence of node
positivity compared with other paratesticular patients
(Weiner,in preparation).Suprarenal nodes should be
incorporated into this sample because positive nodes
higher than the renal vessels are considered dissemi-
nated metastatic disease and patients are classi￿ ed as
Group IV. Inguinal nodes rarely are involved and are
biopsied only if clinically positive or if the scrotum is
invaded by tumor. Inguinal nodes are not considered
regional, and  having  positive  nodes  changes  the
patient to Group IV.
Resection of the hemiscrotal skin and contents are
required when there is tumor ￿ xation or invasion, or
when  a  prior  trans-scrotal  biopsy  has  been
performed.When the tumor has been inappropriately
biopsied or removed by a trans-scrotal approach, a
second operation is required including excision of the
hemiscrotum and spermatic cord structures to the
internal ring by an inguinal approach.
Genitourinary:vulva,vagina,and uterus
Usually these tumors are botryoid variants of embry-
onal RMS and have good prognoses, with  survival
>90%.80 In the past,initial excision of a vaginal tumor
often  required  radical  procedures because  of  their
large  size  at  presentation. However, vulva/vagina/
uterus  RMS  responds  well  to  chemotherapy, with
impressive tumor regression that generally precludes
the need for radical operations such as pelvic exenter-
ation.Therefore,these patients should be treated with
initial biopsies followed by aggressive chemotherapy
and radiotherapy with reevaluation for residual dis-
ease  after  several  cycles  of  chemotherapy. Only
13–30% of patients treated with this plan required
subsequent excision of a residual mass.63,34 None had
viable tumor in the resected specimens. Given these
excellent results, the goal of surgery is local tumor
resection  while  maintaining  function.81,82 Usually
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.vaginectomy and hysterectomy only need to be per-
formed for persistent or recurrent disease. Primary
uterine tumors might be less responsive to chemother-
apy  than  vaginal  tumors  and  more  often  require
aggressive resection. For uterine lesions treated with
hysterectomies, preservation of the distal vagina and
ovaries is usually possible. Direct tumor involvement
is the only indication for oophorectomy.
Metastatic disease
RMS most commonly metastasizes to lungs, bones,
brain, liver, and lymph nodes by hematogenous and
lymphatic  routes. Unlike  osteogenic sarcomas  and
some other soft  tissue sarcomas, RMS and Ewing
sarcoma are relatively sensitive to chemotherapy and
radiotherapy. Therefore, although  resection  of
metastatic disease for osteogenic sarcoma has been
bene￿ cial, the same advantage has not been shown
for  RMS.83,84 The  only  indication for  resection of
metastatic  disease  is  for  pathological  diagnosis  or
removal of localized, unresponsive tumor.
Prognosis
Many factors in￿ uence long-term survival of patients
with  RMS, including stage, clinical group, disease
site, tumor  size, patient  age, tumor histology, and
distant metastatic disease. So many disparate prog-
nostic factors have been elucidated that a risk classi-
￿ cation system has been devised that encompasses all
those variables (Table 4).The importance of accurate
risk classi￿ cation and indicated therapy  cannot be
over emphasized because appropriate initial therapy
is a patient’s best chance for cure. The salvage rate
after  relapse  is  a  dismal  10  -  15%.85 To  facilitate
correct placement of patients in IRSG protocols a
web site has been developed that will determine the
best protocol for each patient. Data from the patient
is  entered  and  the  appropriate  protocol  is  deter-
mined.The web site for this program is www.geoci-
ties. com/weisburd_marina/Home.html.
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